Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Coléon, Séverin et al. eBioMedicine, Volume 80, 104062

Findings

“CD40.CoV2 immunization elicited high levels of cross-neutralizing antibodies against SARS-CoV-2, VOCs, and SARS-CoV-1 in K18-hACE2 transgenic mice, associated with viral control and survival after SARS-CoV-2 challenge. A direct comparison of CD40.CoV2 with the mRNA BNT162b2 vaccine showed that the two vaccines were equally immunogenic in mice. We demonstrated the potency of CD40.CoV2 to recall in vitro human multi-epitope, functional, and cytotoxic SARS-CoV-2 S- and N-specific T-cell responses that are unaffected by VOC mutations and cross-reactive with SARS-CoV-1 and, to a lesser extent, MERS epitopes.”